JG
Altimmune Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pemvidutide | Obesity | Phase 2 |
| ALT-400 | Undisclosed Metabolic Indication | Preclinical |
Leadership Team at Altimmune
VK
Vipin K. Garg, Ph.D.
President and Chief Executive Officer
SH
Scott Harris, M.D.
Chief Medical Officer
RE
Richard Eisenstadt
Chief Financial Officer
CM
Cynthia Musante, Ph.D.
Senior Vice President, Research & Development
WS
William Symonds, Pharm.D.
Board Member